Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX
Bamco Inc. NY lifted its holdings in Arcellx, Inc. (NASDAQ: ACLX) by 6.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 550,236 shares of the company's stock after acquiring an additional 32,227 shares during the quarter. Bamco Inc. NY owned
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Baron Health Care Fund Q4 2025 Contributors And Detractors
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.
Here's Why Shares of Arcellx Are Up Almost 80% Today
Shares of a biotech firm are jumping on a down day for stocks.
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't a mystery rally.
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
Gilead to acquire Arcellx for $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
Here is how Arcellx, Inc. (ACLX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Arcellx: Funded Into 2028 With Strong Clinical Data
Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especially against Carvykti's neurotoxicity concerns.
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.48 per share a year ago.
